Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3681-3692

  Brauer, Matthew J ^a   Zhuang, Guanglei ^a   Schmidt, Maike ^a   Yao, Jenny ^a   Wu, Xiumin ^a   Kaminker, Joshua S ^a   Jurinka, Stefanie S ^a   Kolumam, Ganesh ^a   Chung, Alicia S ^a   Jubb, Adrian ^a   Modrusan, Zora ^a   Ozawa, Tomoko ^b   James, C David ^b   Phillips, Heidi ^a   Haley, Benjamin ^a   Tam, Rachel N W ^a   Clermont, Anne C ^a   Cheng, Jason H ^a   Yang, Sherry X ^d   Swain, Sandra M ^e   Chen, Daniel ^a   Scherer, Stefan J ^a   Koeppen, Hartmut ^a   Yeh, Ru Fang ^a   Yue, Peng ^a   Stephan, Jean Philippe ^a   Hegde, Priti ^a   Ferrara, Napoleone ^a   Singh, Mallika ^c   Bais, Carlos ^a   more..

^a GENENTECH INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLACEBO; RECOMBINANT VASCULOTROPIN; SUNITINIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MARKER; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; METASTATIC COLORECTAL CANCER; MOUSE; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VDV GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879850441     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3635     Document Type: Article

References (50)

1. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9. (Pubitemid 26102719)
2. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42. (Pubitemid 26102720)
3. Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico LA, et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 2010;16:3887-900.
4. KimKJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4. (Pubitemid 23132159)
5. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-95. (Pubitemid 46912024)
6. Malik AK, Baldwin ME, Peale F, Fuh G, Liang WC, Lowman H, et al. Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood 2006;107:550-7. (Pubitemid 43076378)
7. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-76.
8. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
9. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002;1:193-202. (Pubitemid 41039165)
10. Shojaei F, Singh M, Thompson JD, Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A 2008;105:2640-5. (Pubitemid 351520566)
11. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21. (Pubitemid 44511625)
12. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76. (Pubitemid 36749215)
13. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38.
14. Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy - evolving view based on clinical trial results. Nat Rev Clin Oncol 2012;9:297-303.
15. Yancopoulos GD. Clinical application of therapies targeting VEGF. Cell 2010;143:13-6.
16. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
17. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012;72:1909-14.
18. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007;25:911-20. (Pubitemid 47236916)
19. Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 2007;104:3478-83.
20. Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006;281:6625-31. (Pubitemid 43847597)
21. Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010;141:166-77.
22. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dutoit S, editors. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005. p. 397-420.
23. Kang YH, Ji NY, Han SR, Lee CI, Kim JW, Yeom YI, et al. ESM-1 regulates cell growth and metastatic process through activation of NF-kappaB in colorectal cancer. Cell Signal 2012;24:1940-9.
24. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-77. (Pubitemid 46622044)
25. Yang SX, Steinberg SM, Nguyen D, Wu TD, Modrusan Z, Swain SM. Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res 2008;14:5893-9.
26. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
27. Jakobsson L, Bentley K, Gerhardt H. VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans 2009;37(Pt 6):1233-6.
28. Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM, et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol 2010;12:943-53.
29. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083-7. (Pubitemid 46018529)
30. Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther 2010;10:305-17.
31. Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011;12:256-62.
32. Grunwald V, Merseburger AS. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. Onco Targets Ther 2012;5:111-7.
33. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006;34:532-7. (Pubitemid 43145635)
34. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, WongR, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
35. del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, et al. Identification and functional analysis of endothelial tip cellenriched genes. Blood 2010;116:4025-33.
36. Lobov IB, Cheung E, Wudali R, Cao J, Halasz G, Wei Y, et al. The Dll4/Notch pathway controls postangiogenic blood vessel remodeling and regression by modulating vasoconstriction and blood flow. Blood 2011;117:6728-37.
37. Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 2010;115:5102-10.
38. Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature 2012;484:110-4.
39. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010;465:483-6.
40. Stenzel D, Franco CA, Estrach S, Mettouchi A, Sauvaget D, Rosewell I, et al. Endothelial basement membrane limits tip cell formation by inducing Dll4/Notch signalling in vivo. EMBO Rep 2011;12:1135-43.
41. Franco M, Roswall P, Cortez E, Hanahan D, Pietras K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 118:2906-17.
42. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007;11:539-54. (Pubitemid 46856908)
43. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91:1071-121.
44. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
45. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
46. Chung AS, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D, et al. Differential drug class-speci fic metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol 2012;227:404-16.
47. Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012;21:66-81.
48. Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol 2012;227:417-30.
49. Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT. Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep 2013;3:277-81.
50. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent Bevacizumab. J Clin Oncol 2013 31:1219-30.